ARAY

Accuray Inc. designs, develops & sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company's product suite includes the CyberKnife Systems and the TomoTherapy Systems. It primarily generates revenues by selling the CyberKnife & TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linacs for other uses. It also offers optional hardware and software, technical enhancements and upgrades to the CyberKnife & TomoTherapy System. The CyberKnife Systems include: the CyberKnife G4, CyberKnife VSI System and the new CyberKnife M6 Series System. TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical intensity modulated radiation therapy; the TomoHD System and the Tomo H Series Systems....

+See More

Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 28 June 2025